普萊柯(603566.SH)放棄參股公司增資優先認購權
格隆匯8月25日丨普萊柯(603566.SH)公佈,中科基因向餘江匯澤及其關聯公司借款本金及利息合計不少於2814.69萬元。為處理上述債務,中科基因計劃增資2500萬元,關聯方餘江匯澤擬以2750萬元認繳新增的2500萬元註冊資本,公司放棄優先認購權,該事項構成關聯交易。
中科基因主要從事獸醫診斷領域的獨立實驗室連鎖運營及診斷產品開發等,尚需要在全國各地開展獨立實驗室建設、診斷試劑產品開發、相關軟件開發、動物疫病防控服務工程師和實驗室操作人員體系建設等方面進行大規模的資金投入,未來盈利能力及盈利時點尚存在不確定性。
截至2019年6月30日,中科基因一年內到期的有息債務為3,113.54萬元,根據中科基因目前的盈利能力和現金流情況,存在較大的債務風險,如中科基因未能及時獲得新的債權或股權融資,將會面臨資金枯竭、業務停滯的局面。基於上述原因,普萊柯放棄此次中科基因增資優先認購權,有利於降低上市公司投資風險,保護中小股東權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.